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Different organic and inorganic selenocompounds have been 
reported as anticancer agents
1-2
, and many of them have 
interesting applications in human health
3
. Sodium selenite
4-7
, 
sodium selenide
8
 and elemental Se-nanoparticles
9-11
 can be cited 
as examples of inorganic selenium-containing compounds with 
anticancer and/or apoptotic and/or antibacterial activity.  
Alternatively, among the active organic selenium derivatives, 
methylseleninic acid
12-14
, selenocyanates
15-17
, selenoureas
18,19
 and 
selenoesters
20-21
 can be highlighted. The reported mechanisms of 
action for these compounds vary greatly: reduction of oxidative 
stress
22
, induction of mutations
23
, angiogenesis inhibition
16,24
, 
apoptosis induction
25
 and reversal of multidrug resistance 
(MDR)
25
. Interestingly, selenium and Se-containing compounds 
are like a double-edged sword
26
: they can exert an antioxidant 
action that prevents cancer in normal cells
1-3,22,26
, whereas they 
can act in cancer cells as pro-oxidants that generate reactive 
oxygen species (ROS). These Se-induced ROS can then trigger 
apoptotic processes
25,26
 and can induce mutations in DNA, as 
well as DNA breaks
23,26
. 
The multidrug resistance of cancers and bacterial infections is 
an increasing and troublesome problem nowadays, due to the 
appearance of resistant cancers and resistant bacterial strains
27-28
. 
It has been observed that one of the most common mechanisms 
of cancer MDR is the over-expression of the efflux pumps
29
, 
which are membrane proteins that can recognise and extrude out 
of the cells toxic agents such as the anticancer drugs
29,30
. In this 
context, different studies
6,7,14-16,31-33 
pointed out that 
selenocompounds can enhance the activity of the drugs used in 
cancer chemotherapy in a synergic way if they are applied 
together. Some examples of studies that have shown this 
synergistic enhancement of the chemotherapy drugs action are: 
(i) sodium selenite potentiates the cytotoxicity of imatinib in 
HCT116 colorectal cancer cells
6
; (ii) sodium selenite  enhances 
the cytotoxicity of cisplatin in MCF-7 breast carcinoma cells
7
; 
(iii) the cytotoxicity of paclitaxel is augmented in presence of 
methylseleninic acid in MDA-MB-231 breast adenocarcinoma 
cells
14
; (iv) the combined treatment of mice with diphenylmethyl 
selenocyanate and cisplatin decreases the size of induced 
tumours
15
; (v) a complex organoselenocyanate inhibited the 
angiogenesis and enhanced the therapeutic efficacy of 
cyclophosphamide in tumour bearing Swiss albino mice
16
; (vi) 
selenocystine can potentiate the capacity of auronafin to induce 
apoptosis in A549 lung cancer cell line
31
, (vii) selenocystine also 
enhances the therapeutic effect of doxorubicin in liver carcinoma 
HepG2 cell line
32
; and (viii) Se-methylselenocysteine increases 
the antitumour activity of different chemotherapeutic agents in 
vivo (cisplatin, cyclophosphamide, oxaliplatin and irinotecan) in 
mice
33
. 
Taking in mind the aforesaid antecedents, and seeking to 
determine the influence of selenocompounds on multidrug 
resistance, we evaluated the capacity of a cyclic selenoanhydride 
and ten selenoesters
20,21
 to inhibit a MDR efflux pump such as the 
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ABCB1 (ATP Binding Cassette Subfamily B Member 1) protein 
in MDR mouse T-lymphoma cells as shown previously
25
; as well 
as their capacity to trigger apoptotic events in these mouse T-
lymphoma cells
25
. Results showed a noteworthy and promising 
activity, as the four most active compounds (1, 9-11, Figure 1) 
exerted a (1.7–3.6)–fold stronger efflux pump inhibitory activity 
than the reference verapamil at concentration 10-fold lower. In 
addition, those four most active selenium derivatives triggered 
apoptotic events in more than the 80% of the gated cells
25
.   
Herein we have evaluated these selenocarbonyl derivatives  
1-11 (Table 1) in a human MDR cell line of colon 
adenocarcinoma: the Colo 320/MDR-LRP cell line resistant to 
doxorubicin over-expressing ABCB1 (MDR1)-LRP
27,34
. The aim 
of our study is to compare the MDR reversing and efflux pump 
inhibiting properties of selenocompounds 1-11 in human cancer 
cell lines with the previous results in mouse cells
25
, as well as to 
evaluate their cytotoxicity in normal cells to determine their 
selectivity. For comparison, four additional compounds have 
been chosen as references to estimate the role of the presence of a 
selenium atom (Table 1). On one hand, the phthalic anhydride 
(12) has been selected as the oxygen isoster of the 
selenoanhydride 1. On the other hand, three inorganic 
compounds that represent different chalcogen cyanates have been 
evaluated, as follows: potassium cyanate (KOCN, 13), 
ammonium thiocyanate (NH4SCN, 14) and potassium 
selenocyanate (KSeCN, 15). 
Table 1. Structure of the selenocarbonyl-containing compounds 
evaluated as multidrug resistance (MDR) reversing agents. 
 
 
 
 
 
 
 
 
 
 
 
 
Cpd Group n  X  R1  R2 
1 A - - - - 
2 B 0 S 5-COSeCH3 -H 
3 B 1 N 6-COSeCH3 -H 
4 B 1 C 3-COSeCH3 -H 
5 B 1 C 4-COSeCH3 -H 
6 B 1 C -H -CONH2 
7 B 1 C 4−Cl -COOCH3 
8 B 1 C -H -COOPh 
9 B 1 C 4−Cl -COCH3 
10 B 1 C 4−Cl -COC(CH3)3 
11 B 1 C 3,5-diOCH3 -COC(CH3)3 
Cpd: Compound. 
In this study we evaluate a series of the selenocompounds 
previously reported
20,21
 that showed activity
25
 as novel efflux 
pump inhibitors in parental L5178Y mouse T-lymphoma cells 
and in its MDR subline that expresses the ABCB1 protein after 
being transfected with the human ABCB1 gene
35
. Thus, the 
selenocarbonyl compounds 1-11, shown in Table 1, have been 
examined in different biological studies at the ABCB1-
overexpressing Colo 320/MDR-LRP resistant cell line, as well as 
the equivalent sensitive cell line (Colo 205 doxorubicin sensitive 
cells), following previously described methodologies
25,27,34-38
. The 
selected derivatives 1-11 included the selenoanhydride 1 and the 
selenoesters 2-11, whose alkyl moiety contains different 
functional groups: a methyl group in 2-5, a methylcarbamoil 
group in 6, a methyloxycarbonylmethyl group in 7, a 
phenyloxycarbonylmethyl group in 8 and different ketone-
containing alkyl groups in 9-11. The selenocompounds 1-11 were 
synthesized according to the methods described earlier
20,21
.  
The following biological evaluations were considered in this 
study: the assessment of their cytotoxicity, the inhibition of 
ABCB1 protein, and the ability of the compounds to induce 
apoptotic events. These biological activities were determined 
using rhodamine 123 accumulation assay, MTT method and flow 
cytometry measurements. Besides, the selectivity of the 
compounds towards cancer cells compared to normal cells was 
evaluated using the non tumoral MRC-5 human embryonic lung 
fibroblast cell line, as described previously
39
. The different 
selectivity indexes (SI) were calculated as the quotient of the IC50 
value in the non-tumoral cells divided by the IC50 in the MDR 
cancer cell line. The compounds activity towards cancer cells is 
considered as strongly selective if the selectivity index (SI) value 
is higher than 6, moderately selective if 3 < SI < 6, slightly 
selective if 1 < SI < 3 and non-selective if SI is lower than 1
40
. 
Previously reported studies
41-43
 have evaluated the selectivity of 
novel antiproliferative and cytotoxic agents towards 
colon/colorectal cancer cells using human
41
 or murine
42-43
 
fibroblasts as non-tumoral cell lines. Among them, Meker et al.
41 
compared the antiproliferative activity of novel titanium 
complexes in HT-29 colon adenocarcinoma cells and in MRC-5 
human non-tumoral lung fibroblasts. In addition, our group 
determined the selective action of different selenium compounds 
between CT-26 murine colon carcinoma cells and NIH-3T3 
murine fibroblasts (data not published yet). Based on these lines 
of evidence, we have chosen the MRC-5 cell line to evaluate the 
selectivity of the selenocompounds 1-11 towards the colon 
adenocarcinoma cell lines Colo 205 and Colo 320. 
 
 
 
 
 
 
 
 
Figure 1. Chemical structure of the most active selenocompounds. 
 
The rhodamine 123 accumulation assay
25,34-37
 was selected to 
determine the capacity of compounds 1-11 to inhibit the 
extrusion of the dye (an ABCB1 substrate) out of the MDR Colo 
320 cancer cells. Verapamil was chosen as positive control. To 
determine the activity of these derivatives, the fluorescence 
intensity emitted by the treated cells was measured and the mean 
for the treated cells was calculated and compared with the 
untreated cells. Results were given in terms of the fluorescence 
activity ratio (FAR), as indicated in equation (1). Once the FAR 
values were determined, they are divided by the FAR of 
verapamil, as showed in equation (2), to calculate the FAR 
quotient. The values determined for the compounds evaluated are 
provided in Table 2.  
Table 2. Fluorescence activity ratios calculated for selenocarbonyl 
compounds in rhodamine 123 retention assay using multidrug 
resistant human Colo 320/MDR-LRP colon adenocarcinoma cells. 
Sample 
Concentration 
(μM) 
FAR1 
FAR  
Quotient 
(%)2 
1 2 3.86 135.4 
1 20 12.3 431.9 
2 2 0.64 22.46 
2 20 0.59 20.70 
3 2 0.55 19.30 
3 20 0.63 22.11 
4 2 0.53 18.60 
4 20 0.68 23.86 
5 2 0.55 19.30 
5 20 0.58 20.35 
6 2 0.60 21.05 
6 20 0.58 20.35 
7 2 0.79 27.72 
7 20 0.75 26.32 
8 2 0.75 26.32 
8 20 1.94 68.07 
9 2 11.4 401.1 
10 2 6.19 217.2 
11 2 6.49 227.7 
12  2 0.50 10.83 
12 20 0.73 15.70 
13 2 0.76 16.49 
13 20 0.70 15.09 
14 2 0.61 13.16 
14 20 0.41 8.93 
15 2 0.88 19.12 
15 20 0.61 13.14 
Verapamil 3 20 2.85 100.0 
Verapamil4 20 4.63 100.0 
DMSO3 2 V/V% 0.53 18.60 
DMSO4 2 V/V% 0.59 12.72 
1FAR: Fluorescence activity ratio, calculated as follows: 
  
controltreated
controltreated
sensitivesensitive
MDRMDR
FAR 
 
2Calculated as follows: 
100
verapamil
compound
FAR
FAR
Quotient
 
3Values obtained during the assays for the series of compounds 1-11. FAR 
quotients of compounds 1-11 are calculated in respect to verapamil3   
4Values obtained during the assays for the additional compounds 12-15. FAR 
quotients of compounds 12-15 are calculated in respect to verapamil4. 
Additionally, Figure 2 compares the activity of the most 
potent inhibitors in colon adenocarcinoma cells with that in 
MDR-derived mouse T-lymphoma cell line
25
. 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 2. FAR quotient values, expressed in terms of percentages  
in respect to verapamil tested at 10-fold higher concentration 
(activity of verapamil = 100%), calculated for the most active 
compounds (1, 9-11) in MDR mouse T-lymphoma cell line25 and in 
MDR Colo 320 cells. 
 
According to the results obtained, the most active compounds 
(1 and 9-11) showed a strong efflux pump inhibition: (1.3-4.0)-
fold higher compared to verapamil at a concentration 10 times 
lower. The inhibiting activity of selenoanhydride 1 was 4.32-fold 
stronger than that of verapamil when tested at the same 20 μM 
concentration (9-11 were not tested at 20 μM as they had IC50 
values more than 10 times lower than this concentration). The 
ABCB1 inhibition measured at 2 μM concentration for the active 
compounds (1 and 9-11) in MDR Colo 320 cells indicated a 
significant increase of the inhibiting activity of 9-11 in 
comparison to that described for the ABCB1-transfected mouse 
T-lymphoma cells
25
. As shown in Figure 2, the highest 
improvement was found in the case of derivatives 10 and 11, 
where the inhibition compared to verapamil, raised from 34% to 
217% and from 46% to 228%, respectively. On the other hand, 
derivatives 2-7 exerted a low modulating action on the ABCB1 
efflux pump, as their pump inhibitory action varied from 18% to 
28% of the inhibitory action exerted by the reference verapamil. 
In addition the phenoxycarbonyl selenoester 8 showed a 
significant inhibition of the efflux pump (68.1% of verapamil 
activity at the same concentration - 20 μM).  
In accordance to the results obtained for MDR mouse T-
lymphoma cells, these results show that the four derivatives with 
potent efflux pump inhibitory activity are the cyclic 
selenoanhydride 1, and the ketone selenoesters (9-11). The 
selenoesters with secondary non-ketone functional groups (ester, 
amide, or a methyl group) have a weaker MDR reversing 
activity, both in MDR colon adenocarcinoma and in MDR mouse 
T-lymphoma MDR cells. This fact suggests that the influence of 
the selenocarbonyl moiety (selenoanhydride, selenoester) and of 
the secondary carbonyl functional group present in the alkyl 
moiety bound to selenium in the selenoesters seems to be more 
relevant for the efflux pump inhibition than the different 
substituents at the aromatic moiety bound to the carbonyl group 
of the selenoesters evaluated. As proposed earlier
20,25
, the 
(1) 
(2) 
observed changes of the activity with the functional group can be 
explained both by the polarity modulation and by the 
modification of the selenoester hydrolysis exerted by the 
functional group present in the alkyl moiety bound to the 
selenium atom. These modifications in the substituents placed at 
the opposite side of the molecule may exert a minor influence 
over the selenoester, as these substituents are placed at a higher 
distance of the selenium atom than the functional groups of the 
alkyl moiety. Considering the data obtained at 2 μM 
concentration for the efflux pump inhibition using rhodamine 123 
retention assay in Colo 320 cells, the most active compound is 
the methylketone selenoester 9, with a 2-fold stronger efflux 
pump inhibitory activity than the two tert-butylketone 
selenoesters 10 and 11 and with a 3-fold stronger ABCB1 
inhibiting effect than that of the selenoanhydride 1. Among the 
tert-butylketones, there were no significant differences in the 
activity when the 3,5-dimethoxyphenyl moiety of 11 was 
replaced by the 4-chlorophenyl one of 10. In MDR mouse T-
lymphoma cells
25
, 9 is also the most active compound at 2 μM 
with a 2-fold higher activity than 1, but in this case 10 and 11 
showed a much lower inhibition activity (Figure 2).  
Interestingly, the replacement of the Se atom of 1 with an 
oxygen atom (12) practically eliminated the capacity of 1 to 
inhibit the ABCB1 efflux pump. The FAR quotient of 12 was 
much lower than that of 1 at the two concentrations assayed, and 
even 27-fold lower at the 20 μM concentration. A lack of the 
efflux pump inhibitory properties can be observed for the three 
inorganic chalcogen cyanates 13-15, as well. All reference 
compounds (12-15) displayed a very weak ABCB-1 inhibition 
(FAR quotient <20), in the range of DMSO, incomparably lower 
than the active selenoesters 9-11. Although the comparison of 
results for 1 and 12 underlines a crucial and irreplaceable role of 
Selenium within the cyclic anhydrides, results for three cyanates 
13-15 indicate that not only presence but a particular location and 
the type of bonding are responsible for the efflux pump inhibitory 
properties. Hence, the endocyclic position of Se in the vicinity of 
carbonyl groups seems to be very profitable whereas the CN-
neighborhood and significant alkaline properties are unfavorable 
regardless of the chalcogen atom (Se, O or S). These results 
additionally confirmed the inference about the beneficial role of 
the ketone group within Se-compounds for the ABCB-1 
inhibitory properties, coming from the studies on compounds 1-
11 in both T-Lymphoma and Colo-cancer cells. 
The cytotoxicity exerted by the selenocarbonyl compounds    
1-11 in both the sensitive and resistant Colo cells was measured 
using MTT method, and results were given in terms of IC50 
values (Table 3). The three most active derivatives (9-11) had 
IC50 values in nanomolar range in MDR Colo 320 cells. 
Compound 11 was the most potent one with an IC50 of 350 nM. 
In the sensitive cell line, these three compounds showed IC50 
values in the range from 1.19 to 5.48 μM. None of the remaining 
derivatives 1-8 were cytotoxic in the sensitive Colo 205 cell line 
at concentrations lower than the selected threshold (100 μM); and 
only 1 and 4 showed IC50 values below 100 μM against MDR 
Colo 320 cells. At the sight of the results, the ABCB1 efflux 
pump inhibitory activity of the selenoanhydride 1 is truly 
interesting for possible future applications in medicine: 1 exerts a 
1.35-fold and a 4.32-fold stronger pump inhibition than 
verapamil at concentrations 32 times and 3.2 times lower, 
respectively, than the IC50 value determined for 1 in this resistant 
cell line. Interestingly, all the derivatives were more cytotoxic 
against the resistant Colo 320/MDR cell line than against the 
sensitive Colo 205 cells. The ketone selenoester 9 was the most 
selective compound against the MDR cell line, with a selectivity 
index (SI) of 10 to the MDR cells in respect to the sensitive cells.  
Table 3. Cytotoxicity of selenocompounds on sensitive Colo 205 
human colon adenocarcinoma cells, on the resistant Colo 320/MDR 
cell line, and on non-tumoral MRC-5 human embryonic lung 
fibroblasts. Selectivity of the compounds for colon adenocarcinoma 
cell lines in respect to MRC-5 non-tumoral cells.  
Cpd 
A - Colo 
205 
  B - Colo 320  
SI 
 
A/B 
 C - MRC-5  
SI 
 
C/A 
SI 
 
C/B IC50 
(μM) 
SD  
IC50 
(μM) 
SD   
IC50 
(μM) 
SD  
1 >100 -  63.9 2.12  ≥1.6  >100 -  - ≥1.6 
2 >100 -  >100 -  -  4.26 0.65  ≤0.04 ≤0.04 
3 >100 -  >100 -  -  17.9 0.00  ≤0.18 ≤0.18 
4 >100 -  12.5 1.76  ≥8.0  28.4 0.70  ≤0.28 2.3 
5 >100 -  >100 -  -  61.5 2.16  ≤0.62 ≤0.62 
6 >100 -  >100 -  -  76.6 0.92  ≤0.77 ≤0.77 
7 >100 -  >100 -  -  33.4 3.08  ≤0.33 ≤0.33 
8 >100 -  53.7 0.91  ≥1.9  >100 -  - ≥1.9 
9 5.48 0.75  0.55 0.11  10.0  5.35 0.24  0.98 9.7 
10 1.63 0.55  0.96 0.15  1.7  8.10 0.90  5.0 8.4 
11 1.19 0.21  0.35 0.09  3.4  5.04 0.71  4.2 14.4 
12 >100 -  >100 -  -  >100 -  - - 
13 >100 -  >100 -  -  >100 -  - - 
14 >100 -  >100 -  -  >100 -  - - 
15 >100 -  >100 -  -  >100 -  - - 
Cpd: compound, SI: Selectivity Index.   
 
With the exception of derivatives 1 and 8, all compounds 
showed IC50 values below 100 μM in the non-tumoral human 
MRC-5 lung fibroblast cell line. Among them, the IC50 values of 
compounds 3, and 5-7 were from 17 to 77 μM, whereas the IC50 
values of derivatives 2 and 9-11 placed in the 4-8 μM range. It is 
noteworthy that the five most potent ABCB1 efflux pump 
inhibitors (1, 8-11) exert a selective action towards the colon 
adenocarcinoma cells compared to the MRC-5 cells, especially 
against the MDR cell line: 1 and 8 were slightly selective towards 
Colo 320 cells, and 9-11 showed a strong selectivity towards the 
resistant cells (the most selective, 11, had a SI = 14.4). Among 
them, 10 and 11 were moderately selective towards the sensitive 
Colo 205 cell line. In contrast, the remaining selenocompounds 
(2-7) were non-selective, with the exception of 4 on Colo 320 
MDR cells (SI = 2.3, slightly selective). None of the four 
reference compounds evaluated (12-15) showed cytotoxic 
activity in any of the cell lines assayed: the human colon 
adenocarcinoma cells (Colo 205 and Colo 320, Table 3), the 
non-tumoral MRC-5 cells (Table 3) and the mouse T-lymphoma 
cells (PAR and MDR, data now shown). In the case of the pair 
selenoanhydride (1) - phthalic anhydride (12), results highlight 
the importance of the selenium atom to the biological activity.   
Regarding the SAR in the cytotoxicity assay, only the ketone 
selenoesters 9-11 showed IC50 values below 10 μM in both colon 
adenocarcinoma cell lines. The tert-butylketone selenoesters 
were more cytotoxic than the methylketone one in sensitive 
Colo 205 cells. In the resistant Colo 320 cells, with the equivalent 
aromatic substituent (4-chlorophenyl), the methyl ketone 
selenoester 9 was 2-fold more cytotoxic than the tert-butylketone 
10. In addition, the change of the aromatic moiety from the 4-
chlorophenyl (10) to the 3,5-dimethoxyphenyl (11) moiety 
improved the cytotoxicity and converted 11 into the most 
cytotoxic selenocompound. In contrast, the selenoanhydride 1 
was not cytotoxic at concentrations below 100 μM in sensitive 
cells, and was less active (63.9 μM) than 9-11 in resistant cells. 
The SAR analysis for the selectivity towards the cancer cells 
compared to MRC-5 non-tumour cell line is in analogy with that 
one observed for the cytotoxicity in resistant Colo 320 cells. In 
this case, 11 is the most selective compound. 
Table 4. Capacity of the selenocompounds evaluated to induce 
different apoptotic events in MDR Colo 320 cells after 3 hours of 
incubation, measured by flow cytometry.  
 
 Gated events in MDR Colo 320 cells 
Conc 
(μM) 
Early 
aps %) 
Late aps 
necrosis 
(%) 
Cell 
death 
(%) 
Total 
apt 
events 
(%) 
Apt 
quot. 
(%) 
A- I- - 3.42 0.00 0.46 3.42 4.25 
A- I+ - 2.33 0.10 14.0 2.43 3.02 
A+ I- - 23.6 0.00 0.00 23.6 29.3 
A+ I+ - 13.5 5.58 10.5 19.1 23.7 
DMSO 2% 20.3 9.93 4.75 30.2 37.6 
M627 20 58.5 22.0 2.91 80.5 100 
1 2 66.1 5.08 1.41 71.2 88.4 
2 2 12.0 12.5 7.56 24.5 30.4 
3 2 16.3 13.4 5.69 29.7 36.9 
4 2 13.4 15.8 6.37 29.2 36.3 
5 2 16.2 13.5 4.93 29.7 36.9 
6 2 14.3 15.7 4.98 30.0 37.3 
7 2 20.5 14.4 5.55 34.9 43.4 
8 2 16.0 18.6 10.4 34.6 43.0 
9 2 28.9 41.7 15.3 70.6 87.7 
10 2 28.8 35.8 15.4 64.6 80.3 
11 2 29.7 41.7 11.6 71.4 88.7 
12 2 3.79 1.09 7.18 4.88 6.06 
13 2 4.11 1.75 7.28 5.86 7.28 
14 2 6.07 1.62 6.98 7.69 9.55 
15 2 4.22 1.40 7.39 5.62 6.98 
A+: Annexin V-FITC staining, A–: without Annexin V-FITC, I+: propidium 
iodide staining, I–: without propidium iodide; Conc: concentration; aps: 
apoptosis; apt: apoptotic; M627: 12H-benzo[α]phenothiazine. ‘Total 
apoptotic events’ is the sum of ‘early apoptosis’ and ‘late apoptosis, necrosis’. 
’Apoptotic quotient’ is the sum of apoptotic events of the compound divided 
by the sum of apoptotic events caused by M627. 
The ability of the compounds to trigger the different apoptotic 
processes in resistant Colo 320 cells was determined using flow 
cytometry. Selenocompounds 1-11 were evaluated at a 2 μM 
concentration, and the apoptotic derivative M627 (12H-
benzo[α]phenothiazine)
38
 was tested as positive control at a 
20 μM concentration. Results are provided in Table 4 and the 
pro-apoptotic activity of the most active derivatives (1, 9-11) in 
MDR-derived mouse T-lymphoma cells
25
 and in the resistant 
Colo 320 human cell line are compared in Figure 3. Like in 
MDR mouse T-lymphoma cells
25
, the selenoanhydride 1 and the 
ketone selenoesters 9-11 showed a strong capacity to trigger 
apoptotic events in resistant colon adenocarcinoma cells. These 
active derivatives induced apoptosis (including early and late 
apoptosis, and necrosis) in 64-72 % of the gated cells, almost in 
the same range than the positive control (80.5 %) but at a 10-fold 
lower concentration, reaching in this way an 80-90 % of the 
action of the positive control M627 at a 10-fold lower 
concentration. As shown in Figure 3, derivatives 10 and 11 were 
clearly stronger apoptosis inducers in colon cells than in T-
lymphoma cells, whereas the M627, 1 and 9 were slightly more 
pro-apoptotic in mouse MDR T-lymphoma cell line. The 
remaining selenoesters 2-8 were moderate apoptosis inducers, as 
they triggered apoptotic events in 24-35 % of cells at a 10-fold 
lower concentration than that of the positive control. Among 
these derivatives, only the selenoesters 7-8 could induce 
apoptotic events in more than one third of the gated cells. Both 
contain a carboxylic ester in the alkyl moiety bound to the 
selenium atom. Finally, the four references 12-15 had no capacity 
to induce apoptotic events in Colo 320 cells as they have 
apoptotic quotients close to negative controls, and as all the 
selenocompounds 1-11 induce apoptotic events in a significantly 
higher percentage than the reference compounds 12-15.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Percentage of cells which undergone apoptotic events 
(early apoptosis and late apoptosis/necrosis) after exposure to the 
compounds 1-11 or to M627 (positive control), in MDR-derived 
mouse T-lymphoma cell line25 (left) and in MDR human Colo 320 
adenocarcinoma cells (right). 
 
In the SAR analysis of the apoptosis induction assays, it is 
noteworthy that the selenoanhydride 1 and the active ketone 
selenoesters 9-11 exerted differential apoptotic actions: in the 
case of the selenoanhydride 1 the early apoptotic processes were 
triggered in the 66.1 % of cells and weakly the late 
apoptotic/necrotic events (5.1 % of cells). On the other hand, the 
ketone derivatives 9-11 were more potent inducers of late 
apoptosis and necrotic processes (35-42 % of cells) than of early 
apoptosis (28-30 % of cells). Both the selenoanhydride 1 and the 
ketone selenoesters 9-11 were stronger inducers of the early 
apoptosis and of the late apoptosis/necrosis, respectively, than the 
positive control M627. Among the ketone selenoesters, the 
methylketone selenoester 9 was more pro-apoptotic than the tert-
butylketone selenoester (10) with the same aromatic substituent. 
But replacing the 4-chlorophenyl substituent of 10 with the 3,5-
dimethoxyphenyl moiety of 11 augments the apoptotic potency to 
convert the compound 11 into the most pro-apoptotic one. 
To conclude, this study in human colonic adenocarcinoma cell 
lines confirms the results previously obtained in MDR mouse T-
lymphoma cells
25
. Among the 11 selenocompounds evaluated, 
the selenoanhydride 1 and the ketone selenoesters 9-11 have 
showed a very interesting activity in the different biological 
assays performed. According to the results presented herein, 
these four active derivatives are more potent inhibitors of the 
ABCB1 efflux pump than the reference verapamil and also 
excellent apoptosis inducers. In addition, the three ketone 
selenoesters 9-11 are potent and strongly selective cytotoxic 
agents, as they showed IC50 values in nanomolar range at the 
resistant Colo 320 cells whereas their IC50 increased to the 
micromolar range in the non-tumour MRC-5 cell line. In 
addition, the replacement of the selenium atom of the 
selenoanhydride 1 by oxygen (12) eliminates the aforesaid 
interesting activities shown by 1. In the case of the inorganic 
chalcogen compounds 13-15, none of them showed activity 
regarding the efflux pump inhibition, cytotoxicity or apoptosis 
induction. The results for selenoanhydride 1 and selenoesters 2-
11 together with those for the additional compounds 12-15 
underline a beneficial role of both Se- and ketone moiety, 
whereas a presence of ester, amide or cyanate moieties as well as 
an absence of selenium result in total decrease of the desirable 
biological actions. These results in a second pair of 
sensitive/multidrug resistant cancer cell lines promote this series 
of selenocompounds (1, 9-11) as promising agents to overcome 
cancer multidrug resistance, giving a new therapeutic 
perspective.  
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